Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract

References

• Cancer stat facts: female breast cancer. [cited 2022 May 27]. Available from: https://seer.cancer.gov/statfacts/html/breast.html.
   Google Scholar
• Genazzani AR, Schneider HP, Panay N, et al. The european menopause survey 2005: women’s perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol. 2006;22(7):1–6.
   Web of Science ®Google Scholar
• Appel K, Veit J, Diaz P, et al. Purified and specific cytoplasmic pollen extract, PureCyTonin®, inhibits serotonin reuptake in the rat brain model. GREM Gynecol Reprod Endocrinol Metab. 2020;01(2020):64–68.
   Google Scholar
• Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric. 2005;8(2):162–170.
   PubMed Web of Science ®Google Scholar
• Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract serelys((R)) in the management of women with menopausal symptoms. Gynecol Endocrinol. 2019;35(4):360–363.
   PubMed Web of Science ®Google Scholar
• Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96(7):1226–1235.
   PubMed Web of Science ®Google Scholar
• Gold EB, Crawford SL, Leung K, et al. Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. Breast Cancer Res Treat. 2022;191(1):125–135.
   PubMed Web of Science ®Google Scholar
• Seib C, Porter-Steele J, McGuire A, et al. Menopausal symptom clusters and their correlates in women with and without a history of breast cancer: a pooled data analysis from the women’s wellness research program. Menopause. 2017;24(6):624–634.
   PubMed Web of Science ®Google Scholar
• Regan MM, Price KN, Giobbie-Hurder A, et al., International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011;13(3):209.
   PubMed Web of Science ®Google Scholar
• Yeo W, Pang E, Liem GS, et al. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. Health Qual Life Outcomes. 2020;18(1):24.
   PubMed Web of Science ®Google Scholar
• Glaus A, Boehme C, Thurlimann B, et al. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol. 2006;17(5):801–806.
   PubMed Web of Science ®Google Scholar
• Chang HY, Jotwani AC, Lai YH, et al. Hot flashes in breast cancer survivors: frequency, severity and impact. Breast. 2016;27:116–121.
   PubMed Web of Science ®Google Scholar
• Desai K, Mao JJ, Su I, et al. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors. Support Care Cancer. 2013;21(1):43–51.
   PubMed Web of Science ®Google Scholar
• Seib C, Anderson D, Lee K. Prevalence and correlates of sleep disturbance in postmenopausal women: the Australian healthy aging of women (HOW) study. J Womens Health (Larchmt). 2014;23(2):151–158.
   PubMed Web of Science ®Google Scholar
• Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist. 2006;11(2):96–110.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Petersen L, Bower JE, et al. Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data Over 12 months from the Mind-Body study. J Clin Oncol. 2016;34(8):816–824.
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci. 1990;592:52–86. discussion 123 –1 33.
   PubMed Web of Science ®Google Scholar
• Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health. 2007;10(6):247–257.
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Menopausal hot flashes: a review of physiology and biosociocultural perspective on methods of assessment. J Nutr. 2010;140(7):1380S–1385S.
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Whiteman MK, Tomic D, et al. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril. 2006;85(5):1432–1440.
   PubMed Web of Science ®Google Scholar
• Freedman RR. Physiology of hot flashes. Am J Hum Biol. 2001;13(4):453–464.
   PubMed Web of Science ®Google Scholar
• Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014;142:115–120.
   PubMed Web of Science ®Google Scholar
• Kligman L, Younus J. Management of hot flashes in women with breast cancer. Curr Oncol. 2010;17(1):81–86.
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267–274.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059–2063.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578–1583.
   PubMed Web of Science ®Google Scholar
• Moreno AC, Sikka SK, Thacker HL. Genitourinary syndrome of menopause in breast cancer survivors: treatments are available. Cleve Clin J Med. 2018;85(10):760–766.
   PubMed Web of Science ®Google Scholar
• Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer. 2009;9(2):108–117.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–2370.
   PubMed Web of Science ®Google Scholar
• Reeves KW, Pennell M, Foraker RE, et al. Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv. 2018;12(3):379–387.
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist. 2006;11(6):641–654.
   PubMed Web of Science ®Google Scholar
• Cole KM, Clemons M, Alzahrani M, et al. Vasomotor symptoms in early breast cancer-a "real world" exploration of the patient experience. Support Care Cancer. 2022;30(5):4437–4446.
   PubMed Web of Science ®Google Scholar
• Berger AM, Treat Marunda HA, Agrawal S. Influence of menopausal status on sleep and hot flashes throughout breast cancer adjuvant chemotherapy. J Obstet Gynecol Neonatal Nurs. 2009;38(3):353–366.
   PubMed Web of Science ®Google Scholar
• The hormone therapy position statement of “The North American menopause society" advisory Panel . The 2022 hormone therapy position statement of The North American menopause society. Menopause. 2022;29(7):767–794.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H, Steering H, et al. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453–455.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al., HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–482.
   PubMedGoogle Scholar
• Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269–275.
   PubMed Web of Science ®Google Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;(9):CD004923.
   PubMed Web of Science ®Google Scholar
• Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric. 2009;12(4):310–318.
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818–824.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057–2071.
   PubMed Web of Science ®Google Scholar
• Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380.
   PubMed Web of Science ®Google Scholar
• Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest. 2007;64(4):204–207.
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16(2):495–500.
   PubMed Web of Science ®Google Scholar
• Harris DM, Besselink E, Henning SM, et al. Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood). 2005;230(8):558–568.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12):CD001395.
   PubMed Web of Science ®Google Scholar
• Alipour S, Jafari-Adli S, Eskandari A. Benefits and harms of phytoestrogen consumption in breast cancer survivors. Asian Pac J Cancer Prev. 2015;16(8):3091–3396.
   PubMedGoogle Scholar
• Ruhlen RL, Sun GY, Sauter ER. Black cohosh: insights into its mechanism(s) of action. Integr Med Insights. 2008;3:21–32.
   PubMedGoogle Scholar
• Leach MJ, Moore V. Black cohosh (cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;2012(9):CD007244.
   PubMedGoogle Scholar
• Fritz H, Seely D, McGowan J, et al. Black cohosh and breast cancer: a systematic review. Integr Cancer Ther. 2014;13(1):12–29.
   PubMed Web of Science ®Google Scholar
• Doshi SB, Agarwal A. The role of oxidative stress in menopause. J Midlife Health. 2013;4(3):140–146.
   PubMedGoogle Scholar
• Krotkiewski M, Belboul A, Palm S, et al. The effect of SOD-active plant substance polbax on oxygen free radical (OFR) generation and blood cell rheology. Clin Hemorheol. 1995;4:641–647.
   Google Scholar
• Elia D, Mares P. Assessment of the tolerance and effectiveness of a food supplement sérélys (femal) for menopausal women. Genesis. 2008;35:12–15.
   Google Scholar
• D’Alterio MN, Giancane E, Cornacchia S. “GC fem, PI 82, vitamin E” in menopause treatment: benefits for peri- and postmenopausal neurovegetative symptoms. Multidiscip J Woman’s Health. 2015;4:1.
   Google Scholar
• De Franciscis P, Conte A, Schiattarella A, et al. Non-hormonal treatments for menopausal symptoms and sleep disturbances: a comparison between purified pollen extracts and soy isoflavones. Curr Pharm Des. 2020;26(35):4509–4514.
   PubMed Web of Science ®Google Scholar
• Lello S, Capozzi A, Xholli A, et al., on behalf of Italian Society of Menopause (SIM), the Italian Society of Gynecology of the Third Age of Women (SIGiTE), and the Pollen Extract in Menopause Italian Study Group. The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an italian multicentre prospective observational study. Minerva Obstet Gynecol. 2022;74(6):516–521.
   PubMedGoogle Scholar
• Hellstrom AC, Muntzing J. The pollen extract femal – a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825–829.
   PubMed Web of Science ®Google Scholar
• Seeger H, Ruan X, Neubauer H, et al. Membrane-initiated effects of serelys((R)) on proliferation and apoptosis of human breast cancer cells. Gynecol Endocrinol. 2018;34(4):353–356.
   PubMed Web of Science ®Google Scholar
• Iop A, Driol P, Zacchia A, et al. Cytoplasmic pollen extract for treatment of menopausal symptoms in breast cancer patients: a case series report. EJGO. 2021;42(1):45–49.
   Google Scholar